Loading clinical trials...
Loading clinical trials...
CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zoledronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)
Conditions
Interventions
AXS-02 (oral zoledronate)
Placebo
Locations
44
United States
Tucson, Arizona, United States
Hot Springs, Arkansas, United States
Encinitas, California, United States
La Jolla, California, United States
Los Angeles, California, United States
Napa, California, United States
Start Date
July 1, 2015
Primary Completion Date
January 1, 2019
Completion Date
January 1, 2019
Last Updated
March 23, 2018
NCT07473635
NCT05777889
NCT05052736
NCT04144972
NCT06453447
NCT06393101
Lead Sponsor
Axsome Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions